McKesson Corp.’s board reached a $175 million settlement with investors who claimed directors failed to maintain adequate internal systems for spotting suspicious opioid shipments, as the U.S.’s largest drug distributor continues to grapple with claims it helped fuel a public-health …
Source: Claims Journal